Mesothelioma (malignant, clinical disorder) (disorder)
NERO
Year Started: 2022
Multicentre, 2 arm, open-label UK randomised phase II trial in Mesothelioma patients with any histological subtype and any site, who have previously received an approved systemic therapy containing platinum .
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Local recurrence of malignant tumor of urinary bladder (disorder)
AURORA
Year Started: 2022
Atezolizumab in patients with urinary tract squamous cell carcinoma: a single arm, open label, multicentre, phase II clinical trial
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Psychological data | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | RT | Not applicable | 75% -99% |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | RT | Not applicable | 75% -99% | ||
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |